Abstract

The present invention relates to methods for monitoring a subject who has been diagnosed as having or likely to have neurological motor disease or disorder, the method comprising: obtaining a pose derived from movement data comprising joint location data for a plurality of joints of the subject while performing a balance test; and determining the cosine similarity between the pose derived from the movement data and a reference pose derived from reference movement data, wherein said cosine similarity is indicative of the presence and/or severity of a neurological motor disease or disorder Related systems and clinical methods are also described.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires

Abstract

The present invention relates to the field of diagnostics. Specifically, it relates to a computer-implemented method for assessing Huntington's disease (HD) in a subject comprising the steps of determining a Huntington's disease digital motor score (HDDMS) based on a multitude of digital performance features derived from at least one or more of the following: accelerometer measurements, touch sensor measurements, and/or measurements of time, in a dataset of fine motoric and motoric activity measurements from said subject; comparing the determined HDDMS to a reference; and assessing HD in the subject based on said comparison. Further, the invention contemplates a device and a system for carrying out the afore-mentioned methods and the use of such device or system for assessing Huntington's disease in the subject.

IPC Classes  ?

• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention provides compounds having the general formula (I) wherein A, X1, X2, R1, R2, R3, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.

IPC Classes  ?

• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The present invention relates to novel antibodies which bind to antigens on target cells, such as tumor cells, and which target radionuclides to said cells, to uses of those antibodies as well as methods of making them.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

The invention provides compounds having the general formula (I) or (II) (I) (II) wherein A, A1, X1, R1, R2, R3, R4, R5, and R6 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention provides a drug for treating or preventing cancer, the drug comprising a compound represented by the following formula (1), a salt thereof or a solvate thereof and being used in combination with a molecular-targeted agent, wherein the molecular-targeted agent is at least one member selected from the group consisting of a KRAS-G12C selective inhibitor, a SHP2 inhibitor, a VEGF inhibitor and a PD-1 axis binding antagonist. The present invention provides a drug for treating or preventing cancer, the drug comprising a compound represented by the following formula (1), a salt thereof or a solvate thereof and being used in combination with a molecular-targeted agent, wherein the molecular-targeted agent is at least one member selected from the group consisting of a KRAS-G12C selective inhibitor, a SHP2 inhibitor, a VEGF inhibitor and a PD-1 axis binding antagonist.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A system and method for automated synthesis of a macromolecule from a nucleic acid template is provided, which includes a flow cell with a sipper, a mount with a thermal block, a pump, a selectable valve, a holder, an XYZ gantry, and a controller. The flow cell can be held in a fixed position while the gantry can move the holder to sippers of the flow cell. In this configuration, the sipper length can be reduced or minimized to reduce loss of precious reagents and the synthesized macromolecule.

IPC Classes  ?

• B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus

Abstract

A test carrier system (182) is disclosed. The test carrier system (182) comprises: at least one reaction and measurement cup (184), wherein the reaction and measurement cup (184) is configured for receiving at least one buffer solution (186), wherein the reaction and measurement cup (184) comprises at least one optical window (190) which is received in at least one wall (192) of the reaction and measurement cup (184), the optical window (192) enabling optical analysis of the buffer solution (186); and at least one sample processing unit (110), wherein the sample processing unit (110) is attachable to the reaction and measurement cup (184), wherein the sample processing unit (110) comprises: at least one sample application area (112), wherein the sample application area (112) is configured for receiving at least one sample, wherein the sample application area (112) comprises at least one capillary (114) which opens into an interior space (116) of the sample processing unit (110); and at least one chemical reagent (194), wherein the chemical reagent is received within the interior space (116) of the sample processing unit (110) or within the reaction and measurement cup (184); wherein the test carrier system (182) is configured to be rotatable around a rotation axis (196) of the test carrier system (182) whereby the buffer solution (186) is alternatively transportable to the sample application area (112) or to the chemical reagent (194) depending on at least one of a direction of rotation and a degree of rotation of the test carrier system (182) around the rotation axis (196) of the test carrier system (182).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

A port device (110) for introducing at least one liquid pharmaceutical compound into at least one intraocular space (114) is proposed. The port device (110) comprises: a. a port body (120) providing at least one channel (122) fluidically connecting at least one extraocular port (124) of the port device (110) with at least one intraocular port (126) of the port device (110); b. at least one circumferential flange (128) for attaching the port body (120) to a rim of a scleral opening (118); and c. at least one valve (134) for controlling a flow of the pharmaceutical compound through the channel (122), the valve (134) comprising at least one valve member (136) having a default closed position preventing a flow of the pharmaceutical compound through the channel (122) and an open position permitting a flow of the pharmaceutical compound through the channel (122), wherein the valve member (136) is configured to be reversibly brought from the closed position into the open position by exerting an opening force. Further, a kit (150) for introducing at least one liquid pharmaceutical compound into at least one intraocular space (114) is proposed. The kit (150) comprises at least one port device (110) according to the present invention and at least one applicator device (146). The applicator device (146) is configured to engage with the port device (110). The applicator device (146) is configured to introduce the pharmaceutical compound into the intraocular space (114) through the port device (110).

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

The present invention provides reversible fluorescent probes for cannabinoid receptor 1 ("CB1") having the general formula (I) wherein A and B are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

• C09B 11/08 - Phthaleins
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C09B 69/00 - Dyes not provided for by a single group of this subclass
• C09B 69/10 - Polymeric dyesReaction products of dyes with monomers or with macromolecular compounds
• C09B 11/24 - Phthaleins containing amino groups
• C09B 11/28 - Pyronines
• C09B 23/10 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an even number of CH groups

Abstract

In a first aspect, the invention relates to a filter element, preferably a blood filter element, comprising (A) a porous film, wherein the porous film comprises at least one film forming polymer and at least one film opener and is free of reactive agents; and (B) a porous support. A second aspect of the invention is directed to a process for preparing a filter element according to the first aspect. In a third aspect, the invention relates to a filter assembly, comprising (I) the filter element of the first aspect; and (II) a spreading member (C). A fourth aspect of the invention is directed to the filter element of the first aspect or the filter assembly of the third aspect, being prepared in the form of a sheet or stripe, preferably cuttable and/or punchable sheet or stripe, from which the filter element or the filter assembly is cut and/or punched in required dimensions, wherein the sheet or stripe has larger dimensions regarding length and width than the filter element or the filter assembly, allowing to cut and/or punch out at least one filter element or filter assembly, wherein in case of a filter assembly, the remaining part of spreading member (C) is optionally removed after cutting and/or punching. A fifth aspect of the invention is related to a method for preparing a filter element of the first aspect or the filter assembly of the third aspect. A sixth aspect of the invention relates to a test carrier system comprising the filter element of the first aspect, and a seventh aspect of the invention is related to a plasma separation and metering unit comprising the filter element of the first aspect. An eight aspect of the invention is directed to the use of the filter element of the first aspect or the plasma separation and metering unit of the seventh aspect for separation of blood plasma from whole blood.

IPC Classes  ?

• B01D 39/16 - Other self-supporting filtering material of organic material, e.g. synthetic fibres
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
• B01L 9/00 - Supporting devicesHolding devices
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• B01D 71/48 - Polyesters
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

A plasma separation and metering unit (110) is disclosed. The plasma separation and metering unit (110) comprises: • at least one housing (112), wherein the housing (112) comprises at least one receptacle (114) forming at least one sample port (116) for receiving at least one biological sample (168) comprising plasma (174); • at least one plasma separation element (118), wherein the plasma separation element (118) is received in the receptacle (114) of the housing (112), wherein the plasma separation element (118) comprises a sample application side (120) facing the sample port (116) and a plasma side (122) opposing the sample application side (120); and • at least one plasma metering capillary (124) extending from the housing (112), wherein an application end (126) of the plasma metering capillary (124) is fluidically connected to the plasma side (122) of the plasma separation element (118) and is configured for receiving the plasma separated from the biological sample (168) by the plasma separation element (118), wherein an outlet end (128) opposing the application end (126) of the plasma metering capillary (124) comprises an outlet opening (130), and wherein the plasma metering capillary (124) further comprises at least one lateral opening (148) in a capillary wall (132), the lateral opening (148) being located adjacent to the outlet end (128).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Herein is reported a method for producing a recombinant adeno-associated viral particle (rAAVp) preparation comprising the steps of cultivating a mammalian cell comprising a gene encoding a non-adeno-associated-virus gene, which is operably linked to two AAV inverted terminal repeats (ITRs) (i.e. the non-adeno-associated virus gene is interspaced between the two AAV ITRs), a gene encoding the AAV Cap protein VP1 and/or VP3, a gene encoding the AAV Rep protein Rep78 or Rep68 and/or a gene encoding the AAV Rep protein Rep52 or Rep40, a gene encoding the adenoviral helper function E4orf6, and a gene encoding the adenoviral helper function E2A, recovering the rAAVp from the cell and/or the cultivation medium, and thereby producing the rAAVp preparation, whereby the cultivating of the mammalian cell is in the presence of at least one compound selected from one of the following groups of compounds the caspase inhibitor Q-VD-OPh and IDN6556, DNA damage response activation inducing substances, including ATM/ATR inducing substances, antiviral response inhibitors, AMPK activators, oxidative phosphorylation agents, inhibitors of κB kinase, dNTP synthesis enhancers, including co-factors and building blocks, and cell cycle modulators.

IPC Classes  ?

• C12N 15/86 - Viral vectors

Abstract

The present invention relates to to a computer-implemented method, a computer program, a non-transitory computer-readable storage medium, including instructions, a data processing device, and a health management device for predicting a potential effect and/or future concentration of an analyte in a bodily fluid as well as relates to a health management system for health management of a chronic disease. In order to improve health management, a subject is notified about an at least one upcoming future event and its potential effect on the analyte concentration in the bodily fluid of the subject.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

The present invention relates to a temperature measuring assembly (100) for determining a temperature inside a medical container (20), the medical container (20) having a hollow body (21) with an outer body wall (22) and a body opening (23). The temperature measuring assembly (100) comprises a temperature sensor (40) comprising at least one detector element (42) having a temperature sensing portion (41), and a sensor holder (30) holding the temperature sensor (40). The sensor holder (30) is configured to be installed on the medical container (20) such that it extends through the body opening (23) into the interior of the hollow body (21) and that the temperature sensing portion (41) of the at least one detector element (42) is positioned inside the hollow body (21) at or close to the outer body wall (22) of the hollow body (21). The present invention also relates to a temperature measuring attachment (110) and a temperature measuring system (12) for determining a temperature inside a medical container (20), as well as to a method of temperature monitoring, process validation and/or equipment qualification in connection with handling temperature-controlled medical products using such a temperature measuring assembly (100), attachment (110) or system (120).

IPC Classes  ?

• G01K 1/14 - SupportsFastening devicesArrangements for mounting thermometers in particular locations
• G01K 1/02 - Means for indicating or recording specially adapted for thermometers

Abstract

Hbb]pyrazine compound of formula (I), or a stereoisomer thereof: Formula (I), or a pharmaceutically acceptable salt thereof; and compounds prepared by these processes.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The present invention provides RNA ligase variants and its use in ligation reactions with oligonucleotides.

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The invention allows an increased throughput of diagnostic assays and doubles, triples or even further increases the number of assays per cartridge and may therefore be considered as very environmental- and eco-friendly. At the same time, multiple potentially life-saving test results may be provided for one or more patients. The invention relates to an In Vitro diagnostic (IVD) test system (1a, 1b) for performing a multiplexed diagnostic assay, wherein the IVD test system (1a, 1b) comprises: a test carrier (2) comprising a sample application port (3) configured to receive a sample fluid (30); a test zone (4) comprising a shared recessed assay membrane area (4a) and a sample release port (4b) for releasing at least one portion (30, 30a) of the sample fluid (30) to the shared recessed assay membrane area (4a); and a microfluid sample channel system (5) configured to guide the at least one portion (30, 30a) of the sample fluid (30) from the sample application port (3) to the sample release port (4b); the IVD test system (1a, 1b) further comprising: a first assay membrane (6) positioned in the shared recessed assay membrane area (4a) and configured to receive a first part of the at least one portion (30, 30a) of the sample fluid (30) from the sample release port (4b) and to indicate at least one first analyte (31a) in the first part of the at least one portion (30, 30a) of the sample fluid (30); and a second assay membrane (7) positioned in the shared recessed assay membrane area (4a) next to the first assay membrane (6) and configured to receive a second part of the at least one portion (30, 30a) of the sample fluid (30) from the sample release port (4b) and to indicate at least one second analyte (31b) in the second part of the at least one portion (30, 30a) of the sample fluid (30) and/or to indicate the at least one first analyte (31a) in the second part of the at least one portion (30, 30a) of the sample fluid (30) in a different sensitivity range as the first assay membrane (6).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
• G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
• G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Goods & Services

Pharmaceutical preparations.

Abstract

Computer-implemented methods of providing a clinical predictor tool are described, comprising: obtaining training data comprising, for each of a plurality of patients, values for a plurality of clinical variables comprising a variable indicative of a diagnosis or prognosis and one or more further clinical variables; and training a clinical predictor model to predict the variable indicative of a diagnosis or prognosis using said training data, wherein obtaining the training data comprises obtaining synthetic clinical data comprising values for a plurality of clinical variables for one or more patients by obtaining a directed acyclic graph (DAG) edges corresponding to conditional dependence relationships inferred from real clinical data comprising values for the plurality of clinical variables for a plurality of patients, and obtaining values for each node of the DAG using a machine learning model and multivariate conditional probability table. Computer-implemented methods of obtaining synthetic clinical data are also described.

IPC Classes  ?

• G06F 16/901 - IndexingData structures thereforStorage structures
• G06F 16/906 - ClusteringClassification
• G06N 3/094 - Adversarial learning
• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to the field of polypeptide conjugates, more in particular to conjugates comprising a polypeptide, a nucleic acid and a linker, wherein the conjugation involves a click chemistry between an organic azide and dibenzocyclooctine (DBCO) derivatives. The invention relates as well to methods to obtain such conjugates, as well as to their use in the treatment of a neurological disease, a brain disease, or cancer.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 9/10 - Transferases (2.)
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention relates to a method for detecting an application valve leakage in an analytic system comprising an application valve fluidly connected to an eluent pump, to a trapping column, and to a detector unit, the method comprising (i) applying a sample to the trapping column via the application valve; (ii) applying the sample of step (i) to the detector unit; and (iii) determining at least one sample constituent in the dead time of the analytic system. The present invention also relates to an analytic system comprising an application valve fluidly connected to an eluent pump, a trapping column, and to a detector unit, configured to perform the method according to the present invention, and to methods for quality assurance and uses related thereto.

IPC Classes  ?

• G01N 30/32 - Control of physical parameters of the fluid carrier of pressure or speed
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
• G01M 3/04 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point
• G01M 3/22 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for pipes, cables, or tubesInvestigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for pipe joints or sealsInvestigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using special tracer materials, e.g. dye, fluorescent material, radioactive material for valves
• G01N 30/20 - Injection using a sampling valve

Abstract

The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, R1, and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

• A61P 25/06 - Antimigraine agents
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 471/04 - Ortho-condensed systems

Abstract

The invention relates to a diastereomer of nucleoside triphosphates suitable for use in sequencing by expansion. The diastereomer provides a better acceptance and incorporation by a DNA polymerase and better performance in sequencing by expansion workflows. The invention also relates to sequencing methods using the diastereomer of the nucleoside triphosphates.

IPC Classes  ?

• C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C12Q 1/6869 - Methods for sequencing

Abstract

The present invention relates to a process for the preparation of compound (I), or a pharmaceutically acceptable salt thereof, which is useful for the treatment of medical disorders and diseases, most especially by WRN inhibition.

IPC Classes  ?

• C07D 239/34 - One oxygen atom
• C07B 43/06 - Formation or introduction of functional groups containing nitrogen of amide groups
• C07B 63/00 - PurificationSeparation specially adapted for the purpose of recovering organic compoundsStabilisationUse of additives

Abstract

NN-[(1S,2E)-1-cyclopropyl-3- (methanesulfonyl)prop-2-en-1-yl]-2-(1,1-difluoroethyl)-4-phenoxypyrimidine-5-carboxamideide and solvates thereof, as well as therapeutic uses thereof and pharmaceutical composition comprising them.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 239/34 - One oxygen atom

Abstract

The present invention relates to an automated method for determining a particulate compound in a liquid sample, said method comprising (a) dispensing a thin blot aliquot of said sample on a first working area of a substrate; and/or (b) dispensing an overprint aliquot of said sample on a subarea of said first working area; and/or (c) distributing a thick blot aliquot of said sample on a subarea of said first working area and/or on a second working area of the substrate; and (d) determining the particulate compound in said first working area, in said subarea of said first working area, and/or in said second working area, wherein said dispensing comprises translating an applicator tip in relation to the substrate while dispensing the liquid sample through the applicator tip onto the substrate. The present invention further relates to systems and to diagnostic methods related thereto.

IPC Classes  ?

• G01N 1/28 - Preparing specimens for investigation
• G01N 1/31 - Apparatus therefor
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G06T 7/00 - Image analysis

Abstract

1215144 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.

IPC Classes  ?

• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• C07D 491/08 - Bridged systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/425 - Thiazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

The present invention relates to method for the synthesis of oligonucleotides comprising a modified internucleoside linkage.

IPC Classes  ?

• C07H 1/00 - Processes for the preparation of sugar derivatives
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

A method for evaluating the suitability of auto-exposure settings of a mobile device for performing a color based measurement, the mobile device having at least one camera for capturing an image representative of a scene is described.

IPC Classes  ?

• H04N 17/00 - Diagnosis, testing or measuring for television systems or their details
• H04N 23/61 - Control of cameras or camera modules based on recognised objects
• H04N 23/63 - Control of cameras or camera modules by using electronic viewfinders
• H04N 23/60 - Control of cameras or camera modules
• H04N 23/71 - Circuitry for evaluating the brightness variation
• H04N 23/73 - Circuitry for compensating brightness variation in the scene by influencing the exposure time
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• H04N 1/60 - Colour correction or control
• G01N 21/84 - Systems specially adapted for particular applications

Abstract

The present disclosure relates to the fields of molecular biology and nucleic acid technology. The present disclosure also relates to therapy and prophylaxis of disease.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/86 - Viral vectors
• C12N 15/864 - Parvoviral vectors

Abstract

Disclosed herein is a cell culturing device (1) for culturing cells and/or organoids comprising a cell accommodation unit (2) comprising at least one cell culturing chamber (3) being configured for accommodating a liquid cell culturing medium (9) and a cellular structure, wherein the cell culturing chamber (3) comprises a venting opening (4) being configured for venting the cell culturing chamber; a pressure chamber (5) comprising a pressure chamber inlet (6); a channel (7) connecting the at least one cell culturing chamber (3) and the pressure chamber (5); the cell culturing device further comprising a first pressure generator (8), in particular a pump, being connected to the pressure chamber inlet and being configured for temporarily pressurizing the pressure chamber with a pressure pulse; wherein the at least one cell culturing chamber (3), the pressure chamber (5) and the channel (7) are configured such that the pressure pulse from the first pressure generator (8) propagates from the pressure chamber (5) through the channel (7) to the at least one cell culturing chamber (3) and in particular into the liquid cell culturing medium (9).

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

The present invention concerns the field of point-of-care diagnostics. In particular, it relates to a method for determining an anticoagulant in a blood sample. The method comprises the following steps: a) providing a composition comprising: i) thrombin or a prothrombin activator converting prothrombin into thrombin that is factor Xa (FXa) inhibitor insensitive, or mixtures thereof; and ii) FXa or a prothrombin activator converting prothrombin into thrombin that is FXa inhibitor sensitive, or mixtures thereof; b) contacting a blood sample with the composition thereby generating a mixture of the composition with the blood sample, wherein the mixture comprises at least 0.01 nkat of thrombin activity and at least 0.05 nkat of FXa activity; c) measuring thrombin activity using a substrate capable of detecting thrombin activity; d) comparing the measured thrombin activity to a reference; and e) determining the anticoagulant based on the comparison. Moreover, the invention contemplates a kit for carrying out such methods, working electrodes of an analyte sensor capable of detecting thrombin activity and analyte sensors comprising the same, as well as a devices for determining an anticoagulant in a blood sample.

IPC Classes  ?

• C12Q 1/56 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

Provided herein are methods for library preparation that may be applied to duplex Sequencing by Expansion. In particular, the present invention relates to methods for generating duplex nucleic acid constructs for use as templates for Xpandomer synthesis and nanopore sequence determination thereof that provide sequence information from both strands of a DNA target fragment in a single run. The present invention also provides methods for epigenetic analysis using duplex template constructs that include a parental strand derived from a library fragment that may include modified nucleobases and a newly synthesized complementary daughter copy strand that includes native nucleobases. The present invention also relates to improved reaction conditions for synthesizing Xpandomer copies of the duplex nucleic acid templates. Compositions and kits for use in the methods are also provided.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6855 - Ligating adaptors
• C12Q 1/6869 - Methods for sequencing

Abstract

A transimpedance amplifier circuit (110) is proposed, comprising at least one transimpedance amplifier (112). The transimpedance amplifier comprises at least one variable feedback resistor (114) and at least one operational amplifier (116). The variable feedback resistor (114) is connected between an input of an operational amplifier (116) and an output of the operational amplifier (116).

IPC Classes  ?

• H03F 3/45 - Differential amplifiers
• H03G 1/00 - Details of arrangements for controlling amplification
• H03G 3/30 - Automatic control in amplifiers having semiconductor devices

Abstract

The present disclosure relates to an automated method for applying a liquid sample (1) onto a substrate (2) for image analysis as well as an automated system (100) for performing the automated method. The automated method comprises providing data corresponding to a property of the liquid sample (1) from a property determination unit (20) to a workflow management unit (90); selecting, by the workflow management unit (90), sample preparation operations based on the property of the liquid sample (1); setting, by the workflow management unit (90), operational parameters based on the selected sample preparation operations and/or on the property of the liquid sample (1); controlling a sample preparation unit (10) to prepare the liquid sample (1) for image analysis by performing the sample preparation operations selected by the workflow management unit (90) and by using the operational parameters set by the workflow management unit (90).

IPC Classes  ?

• G01N 1/28 - Preparing specimens for investigation
• G01N 1/30 - StainingImpregnating
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• G01N 1/00 - SamplingPreparing specimens for investigation
• G01N 1/31 - Apparatus therefor
• G01N 1/38 - Diluting, dispersing or mixing samples
• G01N 1/40 - Concentrating samples

Abstract

In one general aspect, the present disclosure relates to an analytical analyzer (100) including a sample support (107) defining a sample area, an illumination assembly (109) configured to illuminate the sample area with illumination light (9), a matrix detector (6) and a detection assembly (111) configured to image light (7) emitted from the sample area onto the matrix detector (6). The analytical analyzer (100) further includes a field lens array including a plurality of field lens elements (202) arranged over the sample area so that the illumination light (9) and the light (7) emitted from the sample traverses through the field lens array (18) and an opaque grid (103) arranged to cover the edges of each of the plurality of field lens elements (202).

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G02B 3/00 - Simple or compound lenses

Abstract

The present invention generally relates to antibodies that bind to CEACAM5. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to methods and compositions for generating duplex nucleic acid template constructs that find use in duplex Sequencing by Expansion and improved reaction conditions for synthesizing Xpandomer copies of the duplex nucleic acid template constructs for nanopore sequencing. Also provided are novel adapter compositions for generating the duplex nucleic acid templates. In particular, provided are extendable Y adapter, cleavable hairpin adapters, and Y-hairpin hybrid adapters. The methods and compositions of the present invention may be used for genetic and epigenetic analysis in a single experiment.

IPC Classes  ?

• C12Q 1/6855 - Ligating adaptors
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present invention relates to an antisense oligonucleotide, wherein the antisense oligonucleotide is 8 to 40 nucleotides in length and comprises a contiguous nucleotide sequence of at least 8 nucleotides in length which is complementary to a region of a UBE3A pre-mRNA transcript, wherein the UBE3A pre-mRNA transcript comprises a duplication of at least 8 nucleotides and the contiguous nucleotide sequence is complementary to at least 8 nucleotides in each duplication.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

Abstract

The invention provides activatable fusion proteins and methods of using the same. The invention further provides anti-huIL-2 antibodies and methods of using them.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/54 - Interleukins [IL]
• C07K 14/55 - IL-2
• C07K 14/56 - IFN-alpha
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons

Abstract

The present invention refers, inter alia, to a method of determining the amount of cardiac Troponin T (cTnT) in a sample, said method comprising a) contacting the sample with an anti-cTnT antibody and with an antibody against skeletal Troponin T (anti-skTnT antibody), wherein the anti-cTnT antibody is capable of binding to a cTnT peptide sequence conserved between cTnT and skTnT, wherein the anti-skTnT antibody is not capable of binding to said conserved cTnT peptide sequence, and wherein the anti-skTnT antibody is capable of binding to a skTnT peptide sequence conserved between skTnT and cTnT, thereby preventing binding of the anti-cTnT antibody to skTnT, and b) determining the amount of cTnT; as well as to uses of said antibodies for determining the amount of cTnT, for preventing skTnT interference in determining the amount of cTnT, and/or for maintaining and/or improving specificity and diagnostic accuracy for a disease associated with cTnT.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention refers, inter alia, to an antibody against skeletal Troponin T (skTnT), wherein the anti-skTnT antibody is not capable of binding to cardiac Troponin T (cTnT). The present invention also relates to uses of said antibodies for determining a skeletal muscle damage, methods of determining the amount of skTnT, wherein the method comprises contacting a sample with at least one of said antibodies, and determining the amount of skTnT. The invention further refers to corresponding polynucleotides encoding for and compositions comprising said antibody. The invention also relates to a computer-implemented method of determining an amount of skTnT using said antibody.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention provides new heterocyclic compounds having the general formula (I) wherein X, Y, A, B, C, and R1 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as soluble epoxide hydrolase inhibitors.

IPC Classes  ?

• C07D 491/20 - Spiro-condensed systems
• C07D 471/10 - Spiro-condensed systems
• C07D 471/20 - Spiro-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

The invention provides antibodies that bind to FolR1, particularly pH responsive anti-FolR1 antibodies and methods of using the same.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention generally relates to novel protease activatable Fc domain binding molecules, polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the molecules of the invention, and to methods of using these molecules in the treatment of disease.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

A process for producing double stranded oligonucleotides is described wherein in an automated crossflow equipment a solution of a first single strand oligonucleotide is continuously crossflow-filtered until a target concentration is reached and thereafter a solution of a second single strand oligonucleotide is continuously crossflow-filtered under conditions which allow annealing until the completion of the annealing is detected.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to methods for determining the brain uptake, likelihood of effectiveness, and dosage of therapeutic agents that are administered intrathecally to the brain of a subject, particularly a human patient. The present invention further provides for the treatment of a subject within a patient subgroup identified by the method of the present invention, and/or with a dosage determined by the present invention.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

A transdermal medical device (110) is proposed, specifically for sampling of capillary blood, comprising at least one stationary component (118) and at least one movable component (120). The movable component (120) is mounted to the stationary component (118) in a movable manner. The movable component (120) is movable from a distal position (154) to a proximal position (156). The movable component (120) comprises at least one penetration element (140) configured for penetrating the skin of a user. The penetration element (140), in the distal position (154) of the movable component (120), is received within the stationary component (118). In the proximal position (156) of the movable component (120), the penetration element (140) protrudes from an application side (168) of the stationary component (118). The movable component (120) further comprises at least one magnetic driver element (138) which is configured such that a movement of the movable component (120) is drivable by at least one external magnetic force. Further, a body mount (112) for attaching the transdermal medical device (110) to a body surface of a user, a transdermal medical kit (114) comprising the transdermal medical device (110) and the body mount (112), and a method of driving a penetration element (140) are proposed.

IPC Classes  ?

• A61B 5/15 - Devices for taking samples of blood
• A61B 5/151 - Devices for taking samples of blood specially adapted for taking samples of capillary blood, e.g. by lancets
• A61M 5/158 - Needles

Abstract

Provided are combination therapies comprising inavolisib and a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive cancers; and methods of treating a PIK3CA mutated, HER2 positive (HER2+) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib and PH FDC SC.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4196 - 1,2,4-Triazoles

Abstract

A method and system for predicting treatment response. Image data comprising an eye of a subject with diabetic macular edema is received. The image data may include color fundus imaging data or optical coherence tomography imaging data. A prediction model that comprises a first machine learning model generates a treatment response prediction of the subject based on the first image input. Medical data corresponding to the subject is received. A treatment response is predicted based on the image data and the medical data using a prediction model comprising a machine learning model.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06T 7/00 - Image analysis

Abstract

A method and system for generating a treatment output for a subject with DME includes receiving OCT imaging data for a retina of a subject at a first and a second point in time. Using the OCT imaging data for the first and second point in time, a first and a second OCT segmented image may be generated using a machine learning model. Based on the first and second segmented OCT images, a first and a second measurement of a DME-associated feature may be generated for the first and second point in time. A reduction between the first and second measurements may be identified and compared to a threshold. A reduction that exceeds the threshold may be associated with an improved vision health metric for the subject at a third point in time. Based on the comparison, a treatment output may be generated.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

The present disclosure relates to analysis of cells obtained by: (a) contacting a population of cells with a plurality of vectors comprising nucleotide sequences providing for targeted integration of a polynucleotide of interest comprising an identifier sequence into the genomic DNA of a cell under conditions suitable for introducing the vectors into the cells, wherein in each vector of the plurality of vectors that comprises a polynucleotide of interest, the identifier sequence is unique; and (b) subjecting the cells obtained after step (a) to selection for cells having integrated a polynucleotide of interest into their genomic DNA, in order to evaluate/monitor and/or manipulate their diversity.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Abstract

Provided are a combination therapy comprising inavolisib, palbociclib and fulvestrant and methods of treating PIC3CA-mutant, hormone receptor positive (HR+) and HER2 negative (HER2-) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib, palbociclib and fulvestrant. The combination therapy produces a statistically significant and clinically meaningful improvement to the patient as compared to administering palbociclib and fulvestrant alone to a comparable patient.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61P 35/00 - Antineoplastic agents

Abstract

A method and system for detecting the presence of diffuse retinal thickness (DRT) in optical coherence tomography (OCT) images. Detecting the presence of DRT in OCT images includes receiving an OCT imaging data for a retina of a subject and forming an image input for a machine learning model (e.g., a deep learning model) using the OCT imaging data. A machine learning model is used to generate a diffuse retinal thickness (DRT) detection output based on the image input. The DRT detection output indicates whether a presence of DRT is detected in the retina of the subject.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• G06N 3/08 - Learning methods
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

The present invention relates to a method for determining hemoglobin in a sample comprising red blood cells, said method comprising (a) dispensing a first aliquot of said sample on a first working area of a substrate; (b) providing a hemolyzed second aliquot of said sample and dispensing said second aliquot on a second working area; and (c) determining the hemoglobin in said first and second working area, wherein said method comprises a further step of contacting said first working area, but not the second working area, with a treatment solution. The present invention also relates to systems and diagnostic methods related to said method.

IPC Classes  ?

• G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
• G01N 1/30 - StainingImpregnating
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

A test element (110) for detecting a fibrinogen level in a sample (112) of a bodily fluid is disclosed. The test element (110) comprises at least one substrate (114) and at least one capillary (116) for receiving and transporting the sample (112). The test element (110) further comprises at least one test region (118) and at least one control region (120) within the capillary (116), wherein the test element (110), in the test region (118), comprises at least two test electrodes (122), wherein the test element (110), in the control region (120), comprises at least two control electrodes (124). The test element (110) further comprises, in the test region (118), at least one detector compound (126), the detector compound (126) being capable of specifically cleaving fibrinogen.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• C12Q 1/56 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

Disclosed are various embodiments for leveraging large language models (LLMs) and retrieval-augmented generation (RAG) for data standardization of clinical AI data. A query comprising a target dataset that needs to be standardized and a dataset dictionary can be obtained. Augmented data can be extracted from an external source. A prompt including the query and the augmented data can be generated and applied to a large language model configured to output a response to the query. The response can include the target dataset standardized according to a standard format.

IPC Classes  ?

• G06F 16/84 - MappingConversion
• G06F 16/9032 - Query formulation

Abstract

The present application discloses solid forms of compound (1), methods for making them, as well as compositions said solid forms.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• C07D 487/04 - Ortho-condensed systems
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam

Abstract

The present invention concerns the field of point-of-care diagnostics. In particular, it relates to a method for determining fibrinogen in a sample comprising the steps of (a) contacting a fibrinogen binding agent, said fibrinogen binding agent comprising a first molecule which is capable of specifically binding fibrinogen and, reversibly bound to the said first molecule, a second molecule which is capable of specifically binding the first molecule, wherein the affinity of said second molecule for the first molecule is lower than the affinity of fibrinogen for said first molecule, with a sample suspected to comprise fibrinogen for a time and under conditions which allow for specific binding of fibrinogen to said first molecule, whereby the second molecule is released from said first molecule and fibrinogen is specifically bound by the first molecule, (b) determining said second molecule released from said first molecule, and (c) determining fibrinogen in the sample based on the released second molecule. The invention further contemplates a method for assessing coagulation defects or disorders in a subject as well as devices and kits for carrying out such methods.

IPC Classes  ?

• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

The present invention relates to methods for synthesizing sgRNA, in particular to large scale methods for synthesizing sgRNA.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Goods & Services

(1) Préparations pharmaceutiques destinées au domaine des neurosciences.

Abstract

A first aspect of the invention is directed to a detection zone of a lateral flow immunoassay device comprising a polyion multilayer, the polyion multilayer comprising (i) at least one layer comprising a complex of at least a first polyion and a first member of a binding pair; and (ii) at least one layer comprising a second polyion, which is oppositely charged with respect to the first polyion. In a second aspect, the invention relates to a lateral flow immunoassay device comprising a capillary channel, wherein the capillary channel houses (I) a detection zone as defined in the first aspect; (II) a first reagent zone, which comprises a labeled binding moiety; and (III) a second reagent zone, which comprises a binding moiety carrying a second member of a binding pair; wherein the binding moieties of (II) and of (III) are both capable of binding an analyte of interest, and the second member of a binding pair is capable of binding with the first member of a binding pair of the detection zone; wherein preferably first reagent zone of (II) and second reagent zone of (III) are spatially separated or overlap with each other at least partially. A third aspect of the invention is directed to the use of the lateral flow immunoassay device of the second aspect for determining an analyte in a sample. In a fourth aspect, the invention is related to a method for determining an analyte in a sample, the method comprising (a) contacting a sample with at least a labeled binding moiety and a binding moiety carrying a second member of a binding pair, thereby forming a mixture; (b) contacting the mixture formed in (a) with a polyion multilayer, the polyion multilayer comprising (i) at least one layer comprising a complex of at least a first polyion and a first member of a binding pair, (ii) at least one layer comprising a second polyion, thereby optionally forming complexes; (c) determining the amount of label containing complexes formed in (b); and (d) determining said analyte in a sample based on the result of step (c). A fifth aspect of the invention relates to a kit for determining an analyte in a sample, comprising the lateral flow immunoassay device of the second aspect and a pump, which is connected or connectable to the suction device.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A method for calibrating at least one analyte sensor for detecting at least one analyte in a sample is proposed. The analyte sensor comprises at least one measurement unit configured for generating at least two at least partially independent sensor signals. Each of the independent sensor signals is dependent on a concentration of the analyte. The method comprises the following steps: a) (110) measuring at least two at least partially independent sensor signals (112, 114) by using the measurement unit on at least one reference sample having a known analyte concentration; b) (116) determining a multidimensional calibration trajectory (118) by combining the measured at least two at least partially independent sensor signals (112, 114) by using at least one processing unit.

IPC Classes  ?

• G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

A filling arrangement (1) for filling a drug substance into a primary packaging (8) comprises: a dosing container (2) housing the drug substance; at least one filling tubing (3) having a first longitudinal end, a second longitudinal end and a channel between the first longitudinal end and the second longitudinal end; and at least one feeding needle (41). The first longitudinal end of each of the at least one filling tubing (3) is connected to the dosing container (2). The second longitudinal end of each of the at least one filling tubing (3) is connected to one of the at least one feeding needle (41). An inner surface of the channel of the filling tubing (3) consists of a low hydrogen peroxide retention material.

IPC Classes  ?

• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• A61L 2/18 - Liquid substances
• A61L 29/00 - Materials for catheters or for coating catheters
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61M 39/00 - Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
• B65B 31/02 - Filling, closing, or filling and closing, containers in chambers maintained under vacuum or superatmospheric pressure or containing a special atmosphere, e.g. of inert gas
• B65B 55/10 - Sterilising wrappers or receptacles prior to, or during, packaging by liquids or gases

Abstract

The present invention relates to a method for coating a glass fiber fleece comprising contacting the surface of a glass fiber fleece with a hydrophilic copolymer; and crosslinking the copolymer. The invention further relates to a glass fiber filter, comprising a glass fiber fleece, wherein the surface of the glass fiber fleece is coated with a hydrophilic copolymer; and to a device for biomedical filter applications comprising the same.

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 39/20 - Other self-supporting filtering material of inorganic material, e.g. asbestos paper or metallic filtering material of non-woven wires
• B01D 69/10 - Supported membranesMembrane supports
• B01D 71/40 - Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
• B01D 71/76 - Macromolecular material not specifically provided for in a single one of groups
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Goods & Services

Pharmaceutical preparations.

Abstract

Computer-implemented methods and systems for identifying and characterizing spectral peaks in a spectrum are disclosed. In particular, methods for use in the field of analytical chemistry for identifying and characterizing peaks in liquid chromatograms, gas chromatograms, mass chromatograms or optical or other spectra without input from or intervention of a user are also described.

IPC Classes  ?

• G01N 30/86 - Signal analysis

Abstract

A kit comprising an in-vitro diagnostic (IVD) consumable device in an environmentally sealed package, where after opening of the package usability of the IVD consumable device by an IVD analyzer is time-limited within an out-of-package usability time period. The package comprises a package mark, the reading of which triggers the start of the out-of-package usability time period, and the IVD consumable device comprises a consumable-device mark, linked to the package mark, the reading of which determines a time lapse since reading of the package mark and whether the time lapse is within or outside of the out-of-package usability time period. A respective IVD analyzer and a respective method of using the kit together with the IVD analyzer, are herein also disclosed.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

Abstract

The present disclosure relates to performing endpoint genotyping based on a Gaussian mixture model (GMM). As one example, a method includes: obtaining, using a processor, cross-talk corrected fluorescent PCR data for an assay; determining, using the processor, a plurality of values based on the cross-talk corrected fluorescent PCR data; generating, using the processor, an assay based on the plurality of values; determining, using the processor, a genotype of a sample based on one or more gray-zones and at least one value associated with the sample; and displaying the genotype determination on a user display.

IPC Classes  ?

• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16B 25/20 - Polymerase chain reaction [PCR]Primer or probe designProbe optimisation

Abstract

The present disclosure relates to classifying genotypes on an assay plate according to predefined standards. As one example, a method includes: obtaining all raw melt curves for an assay plate from a memory; determining melting peak curves for all standards and unknown samples; calculating a median or mean peak curve for each of the standards based on a plurality of replicate melting peak curves of each standard; calculating at least one correlation coefficient between each of the unknown samples and the median standards; comparing the correlation coefficient to a threshold level for each standard; and assigning the unknown sample a genotype of the standard when the unknown sample has a correlation coefficient greater than the threshold level.

IPC Classes  ?

• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism

Abstract

The present disclosure relates to determining crosstalk coefficients for an analyzer based on customer data. In an aspect, a method includes obtaining a manufacturer defined temperature matrix for an analyzer. The method also includes obtaining a customer defined temperature matrix. The method also includes generating a custom temperature dependent crosstalk matrix for a customer. The method further includes performing, based on the custom temperature dependent crosstalk matrix, a matrix inversion and dot matrix multiplication to generate a crosstalk corrected customer fluorescence vector. The method further includes modifying manufacturer defined temperature dependent crosstalk coefficients on the analyzer based on the crosstalk corrected customer fluorescence vector.

IPC Classes  ?

• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/64 - FluorescencePhosphorescence
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

NSSSSMSS)-1-methoxyethyl]-3-pyridyl]-18,18-dimethyl-9,15-dioxo-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27NN-methyl-piperidine-4-carboxamide.

IPC Classes  ?

• C07D 487/18 - Bridged systems
• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• C07K 5/02 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link
• A61P 35/00 - Antineoplastic agents
• A61K 31/504 - PyridazinesHydrogenated pyridazines forming part of bridged ring systems
• A61K 38/12 - Cyclic peptides

Abstract

An IVD system comprising an IVD analyzer and an IVD consumable device configured to be used together with the IVD analyzer in order to carry out an IVD test that enables to obtain reliable test results by more reliably determining whether the IVD consumable device is within or outside of an out-of-package usability time period. In particular, the IVD analyzer comprises an optical detector for determining an optically detectable property of at least one indicator, at least one environmental sensor configured to determine a value of at least one environmental parameter affecting change of the optically detectable property over time and a controller configured to correlate the optically detected property of the at least one indicator to the determined value of the at least one environmental parameter by reference to a stored indicator-specific calibration of the optically detectable property obtained under varying values of the at least one environmental parameter.

IPC Classes  ?

• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• G01N 21/84 - Systems specially adapted for particular applications
• G04F 13/00 - Apparatus for measuring unknown time intervals by means not provided for in groups

Abstract

111 and n are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 493/10 - Spiro-condensed systems
• C07D 495/04 - Ortho-condensed systems
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides reversible fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I), wherein A, R2and R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

• C09B 11/08 - Phthaleins
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C09B 69/00 - Dyes not provided for by a single group of this subclass
• C09B 69/10 - Polymeric dyesReaction products of dyes with monomers or with macromolecular compounds
• C09B 11/24 - Phthaleins containing amino groups
• C09B 11/28 - Pyronines

Abstract

The present invention relates to spirocyclic barbiturates of the general formula (I) or a pharmaceutically acceptable salt thereof, as MMP9 inhibitors for the treatment of ocular surface diseases, such as e.g. dry eye disease.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/10 - Spiro-condensed systems
• C07D 491/10 - Spiro-condensed systems
• C07D 491/20 - Spiro-condensed systems
• C07D 498/10 - Spiro-condensed systems
• A61P 27/04 - Artificial tearsIrrigation solutions
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

The invention relates to a calibration target (1) for calibrating an analytical device (20), wherein the calibration target (1) comprises an electrophoretic display (2) comprising first particles (P1) and second particles (P2), wherein the first particles (P1) and the second particles (P2) differ in at least one property, wherein the electrophoretic display (2) is controllable for displaying a calibration image (I) using the first particles (P1) and/or the second particles (P2).

IPC Classes  ?

• G02F 1/167 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on translational movement of particles in a fluid under the influence of an applied field characterised by the electro-optical or magneto-optical effect by electrophoresis
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G02F 1/1675 - Constructional details

Abstract

The present invention relates to a multispecific antibody that binds to human serum albumin (HSA) and a second antigen, wherein the apparent affinity of the antibody to the second antigen is higher in presence of the mean concentration of HSA in human cerebrospinal fluid as compared to the affinity of the antibody to the second antigen in presence of the mean concentration of HSA in human peripheral blood.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins

Abstract

A method for generating diabetes management parameter user interfaces includes providing stored program instructions of a first diabetes management application (DMA), the first DMA configured to be stored in a memory of an electronic device and, upon execution by a processor, the first DMA is configured to generate a first output display of a plurality of diabetes management parameters corresponding to a time series of analyte data, the plurality of diabetes management parameters depicting a trend of diabetes management parameter levels over time, generate a graphical indicator of a link to a second DMA stored in the memory, and activate the second DMA in response to an input selection of the link, wherein the second DMA is configured to be executed by the processor to generate a second output display of a current-time diabetes management parameter corresponding to the time series of the analyte data stored in the memory.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention provides the use of the compound of formula (I) as defined herein, for detecting the aluminum ion concentration in biological products such as, for example, aqueous antibody compositions.

IPC Classes  ?

• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

Abstract

Disclosed are methods for producing a sensing electrode in which an area of electrode material is applied to a substrate, a sensing chemistry material is applied to cover the electrode material, and a laser is used to form a laser cut the sensing chemistry material and the electrode material in a pattern to define at least a portion of the perimeter of the sensing electrode. The laser cut forms a gap physically and electrically separating the sensing chemistry material and the electrode material inside tire laser cut from the extraneous sensing chemistiy material and the electrode material outside the laser cut. The methods further provide for producing a plurality of sensing electrodes which are separated from a continuous substrate. Further disclosed are the sensing electrodes produced by such methods.

IPC Classes  ?

• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
• G01N 27/327 - Biochemical electrodes
• G01N 27/333 - Ion-selective electrodes or membranes
• B23K 26/38 - Removing material by boring or cutting

Abstract

A computer-implemented method for configuration management of at least one laboratory analyzer system (114) comprising at least one analytical unit (116) is proposed. The method comprises the following steps: a) retrieving at least one item of information on an analytical unit configuration of at least one analytical unit (116) of the laboratory analyzer system (114); b) applying at least one cryptographic function to the item of information on an analytical unit configuration thereby generating a secured item of information on an analytical unit configuration; c) providing the secured item of information on an analytical unit configuration to at least one database (122) of the laboratory analyzer system (114) and/or to at least one remote central database (118), wherein the remote central database (118) is at the manufacturer's site and/or a cloud database.

IPC Classes  ?

• G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
• G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system

Abstract

The present invention relates to compounds of formula (I), wherein R1to R5are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

IPC Classes  ?

• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• C07D 515/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/282 - Platinum compounds
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

R NNNRR)-3-fluoropyrrolidine hydrochloride exhibiting an optical purity of not less than 99.95%-a/a and a purity of not less than 99.5%-a/a thus making it a suitable intermediate for manufacturing of pharmaceutical active compounds.

IPC Classes  ?

• C07D 207/46 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

The present invention provides the use of a sulfone compound for stabilizing a peptide in a sample. Also provided is a corresponding method comprising adding a sulfone compound to a sample for stabilizing the peptide. Also provided is a vessel for collecting a sample comprising a peptide, wherein said vessel comprises a sulfone compound. Provided herein is further a composition comprising a peptide and a sulfone compound, a kit comprising a sulfone compound, a vessel of the invention or a composition of the invention. Finally, the present invention also relates to the use of a sulfone compound for inhibiting a protease.

IPC Classes  ?

• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

Disclosed herein are pharmaceutical compositions and dosage forms including risdiplam that are useful in the treatment of subjects having SMA. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having SMA utilizing the pharmaceutical compositions and dosage forms provided herein.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to systems and methods in the field of digital pathology. It is particularly, but not exclusively, concerned with systems and methods for detecting brain lesions, and in particular brain metastases, in brain digital images.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

Recombinant DPO4-type DNA polymerase variants with amino acid substitutions that confer modified properties upon the polymerase for improved single molecule sequencing applications are provided. Such properties may include enhanced binding and accurate incorporation of bulky nucleotide analog substrates into daughter strands and the like. Also provided are compositions comprising such DPO4 variants and nucleotide analogs, as well as nucleic acids which encode the polymerases with the aforementioned phenotypes.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention provides compounds having the general formula (I), wherein R1, R2, X, and Y are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

IPC Classes  ?

• C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
• C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
• C07D 207/20 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07F 5/02 - Boron compounds
• C07F 7/08 - Compounds having one or more C—Si linkages
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/60 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances involving radioactive labelled substances

Goods & Services

Pharmaceutical preparations.

Abstract

IVA test unit (1) comprising: a test strip (2) for detecting an analyte, wherein the test strip comprises at least an application function, a test reaction function and a test detection function; and a housing (3) for storing the test strip (2) wherein the housing (3) comprises an insert tray (4) and an insert hole (5) for inserting the test strip (2) into the insert tray (4), characterized in that the housing (3) is formed as one single piece.

IPC Classes  ?

• G01N 33/54388 -

Abstract

An elution kit (1) for eluting a biological sample in a liquid (2) and dispensing the eluted sample liquid (2') onto a test element (102) of an analytical kit (101), the elution kit (1) comprises: a sample collection swab (3) for collecting the biological sample, wherein the sample collection swab (3) comprises a stick portion (4) for being hand-held and a deformable head portion (5) on the stick portion (4) for collecting the biological sample, wherein the head portion (5) is porous for the liquid (2); and an elution liquid tube (6) which comprises: an interior space (7) for housing the liquid (2), receiving the sample collection swab (3) and eluting the biological sample in the liquid (2); an insertion opening (10) on a first side of the interior space (7) for inserting the sample collection swab (3) into the interior space (7); a dispense opening (11) on a second side of the interior space (7) adjacent the first side for dispensing the eluted sample liquid; a first closure element (12) to seal the dispense opening (11) in a water-vapor impermeable manner; a second closure element (13) to seal the insertion opening (10) in a water-vapor impermeable manner, wherein the first closure element (12) and/or the second closure element (13) comprises a foil; and the liquid (2), wherein the elution liquid tube (6) contains the liquid (2), wherein the interior space (7) is defined by an inner surface (8) that comprises an elution zone (16) with at least one elution portion (9) having a smallest side-to-side distance y ranging between approximately 70% and 140% of a largest side-to-side distance x of the head portion (5) of the sample collection swab (3) and defining a gap (14) through which the sample collection swab (3) can be pushed and pulled in a closed state of the dispense opening (11).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01L 3/02 - BurettesPipettes

Abstract

The present disclosure provides methods of sequencing one or more target nucleic acid molecules, where each of the one or more target nucleic acid molecules includes one or more modified nucleotides, and wherein the method does not require conversion of any of the one or more modified nucleotides prior to sequencing, and/or does not require any amplification (PCR) cycles prior to sequencing In some embodiments, sequencing is performed with a sequencing-by-tag sequencing device. In other embodiments, sequencing is performed with a Single Molecule Real Time sequencing device.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6869 - Methods for sequencing

Abstract

A method may include generating a training dataset including a pair of sample molecules. The sample molecule pair includes a first molecule and a second molecule. A property computation model is trained to determining a sequence difference comprising a difference between an amino acid sequence of the first molecule and an amino acid sequence of the second molecule. The property computation model is further trained to generate a relative embedding representative of the sequence difference and associating the sequence difference with the sample molecule pair. The property computation model is further trained to determine, based on the relative embedding, a property difference corresponding to a difference between a value of the property exhibited by the first molecule and a value of the property exhibited the second molecule. The trained property computation model may be applied to determine a property difference of a pair of input molecules.

IPC Classes  ?

• G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
• G16B 40/30 - Unsupervised data analysis
• G16B 40/20 - Supervised data analysis
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16C 20/50 - Molecular design, e.g. of drugs
• G16C 20/70 - Machine learning, data mining or chemometrics
• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• G06N 3/08 - Learning methods
• G06N 20/00 - Machine learning
• G16C 20/64 - Screening of libraries
• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes

Abstract

Disclosed herein is a device and method for measuring spatial mass distribution profiles to weigh the accumulated-aggregated mass of an analyte in a crowded bioorganic material background by employing a high frequency recognition pattern. The recognition pattern allows for the Fourier filtering of mass sensitive image data for background and noise subtraction. The device and method enables the screening of a biological fluid sample for an analyte associated with proteinopathy.

IPC Classes  ?

• G01B 9/00 - Measuring instruments characterised by the use of optical techniques
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01Q 60/24 - AFM [Atomic Force Microscopy] or apparatus therefor, e.g. AFM probes
• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• G01Q 60/42 - Functionalisation

Abstract

The invention relates to a novel process for making baloxavir marboxil (1) and baloxavir (1a), as well as to an integrated continuous manufacturing (ICM) implementation thereof. Formulae (1) and (1a), (1) and (1a).

IPC Classes  ?

• C07D 498/14 - Ortho-condensed systems